Novogen (NASDAQ:KZIA – Get Free Report) is expected to be issuing its resultson Friday, September 4th. Analysts expect the company to post earnings of ($0.65) per share and revenue of $0.1340 million for the quarter.
Novogen Price Performance
Novogen stock opened at $12.63 on Wednesday. The firm has a 50-day moving average of $13.43 and a two-hundred day moving average of $11.37. Novogen has a 1 year low of $4.86 and a 1 year high of $17.40.
Analyst Ratings Changes
KZIA has been the subject of several research analyst reports. Canaccord Genuity Group started coverage on shares of Novogen in a research note on Thursday, August 13th. They set a “buy” rating and a $29.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a report on Friday, July 17th. Lake Street Capital began coverage on Novogen in a research report on Thursday, June 11th. They set a “buy” rating and a $32.00 target price for the company. Finally, BTIG Research upped their target price on Novogen from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.33.
About Novogen
Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.
Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.
See Also
- Five stocks we like better than Novogen
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.
